Most of us have heard about Remdesivir and Regeneron, monoclonal antibodies, that are approved by CDC, WHO and FDA for the treatment of Covid-19.

Did you notice any three-letter agency that was left out? It's the National Institutes of Health, NIH.

If you are unfamiliar with the NIH, it is a part of the U.S. Department of Health and Human Services. NIH is the largest biomedical research agency in the world. You may read its mission and goals at this link:

Notice the words "enhance health, lengthen life, and reduce illness and disability." Can you wonder if the federal government of the U.S.A is paying any attention to this mission?

Yes, I'm asking you to research things yourself. Do NOT take my word for it. But please keep reading.

You may have heard of the director, Francis S. Collins, M.D., Ph.D. He recently stepped down from his position.

This is the white-washed official version of why he stepped down:

But just maybe because he was directly or indirectly involved in gain-of-function research, and this is pure speculation on this editor's part, although it is supported by the following link:

Keep reading, you will land on the whole point of this editorial.

Why would the federal government and the three-letter agencies that issue edicts choose Remdesivir and Regeneron as the approved drugs? Again, this is theory on many fronts: Maybe because they are expensive and it's always "Follow the Money?" You, the reader, if you are willing to do a bit of research and delving, can probably find out who in particular, other than the pharmaceutical companies are reaping the rewards of the expensive drugs. Maybe, just maybe people who have invested in those pharmaceutical companies or maybe because they have patents on "diseases" and pharmaceuticals? By the way, a disease cannot be patented, but that's a whole other conversation.

Remdesivir has numerous adverse events, including renal and liver toxicity (which means they can cause kidney or liver failure – two fairly major organs in our bodies). This writer is not making this up, it's in writing that was UPDATED by the NIH on July 8, 2021. [Editor's Note: It is recommended that you do a search, preferably NOT on Google, because it may not lead you to these controversial articles:

Note that at least one of the above articles says that Remdesivir should be used ONLY in a hospital setting. And then the WHO says otherwise in this article:

ADDED: A quote from "From the content (Attorney Tom) Renz presented, the audience learned that 25.9% of patients receiving Remdesivir died while hospitals paid between $2340.00 and $3100.00 for a single patient's course of treatment. This was compared to patients who were treated with Ivermectin, where 3.5% patients died with the cost for hospitals of $24.00 per patient. The question to be answers is: Why would hospitals spend thousands of dollars for a treatment with a high mortality rate, compared to another treatment that has an exceedingly low mortality rate for a much lesser cost? Could it be the fact the Centers for Medicare and Medicaid Services are bribing hospitals to select Remdesivir with a 20% bonus payout they receive by using specific codes to get the money?"

Regen-Cov is under emergency authorization and has not yet been studied well enough to know what adverse reactions can occur, although because the patient is treated with it through injection, it does cause the usual local pain and redness. Adverse reactions are usually specific to the patient.

Again, wondering why everyone is confused?

And finally we get to the point of this article. Note No. 1, in the following link and its adverse effects; then go to No. 2, which is banned by most hospitals in Canada and is very hard to come by in this country, except as a horse dewormer, but is available in Mexico, some have reported.

Interestingly, No. 3 at the above link is also an anti-parisitic drug used to treat extreme diarrhea. This writer has not done extensive research on No. 3.

We come once more to Why? The only logical reason is because ivermectin is inexpensive and has been FDA approved for many years as an essential drug. But Remdesivir and Regeneron are expensive, and although they cause side effects, somebody somewhere is making boatloads of government taxpayer money on them.

Makes you kind of wonder what happened to the mission of enhancing health, lengthening life and reducing illness and disability.

Content on the Beat

WARNING: All articles and photos with a byline or photo credit are copyrighted to the author or photographer. You may not use any information found within the articles without asking permission AND giving attribution to the source. Photos can be requested and may incur a nominal fee for use personally or commercially.

Disclaimer: If you find errors in articles not written by the Beat team but sent to us from other content providers, please contact the writer, not the Beat. For example, obituaries are always provided by the funeral home or a family member. We can fix errors, but please give details on where the error is so we can find it. News releases from government and non-profit entities are posted generally without change, except for legal notices, which incur a small charge.

NOTE: If an article does not have a byline, it was written by someone not affiliated with the Beat and then sent to the Beat for posting.

Images: We have received complaints about large images blocking parts of other articles. If you encounter this problem, click on the title of the article you want to read and it will take you to that article's page, which shows only that article without any intruders. 

New Columnists: The Beat continues to bring you new columnists. And check out the old faithfuls who continue to provide content.

Newsletter: If you opt in to the Join GCB Three Times Weekly Updates option above this to the right, you will be subscribed to email notifications with links to recently posted articles.

Submitting to the Beat

Those new to providing news releases to the Beat are asked to please check out submission guidelines at They are for your information to make life easier on the readers, as well as for the editor.

Advertising: Don't forget to tell advertisers that you saw their ads on the Beat.

Classifieds: We have changed Classifieds to a cheaper and shorter option. Check periodically to see if any new ones have popped up. The former software failed us, so it's just a category now, with prices posted. Send your information to and we will post it as soon as we can. Instructions and prices are on the page.

Editor's Notes

It has come to this editor's attention that people are sending information to the Grant County Beat Facebook page. Please be aware that the editor does not regularly monitor the page. If you have items you want to send to the editor, please send them to Thanks!

Here for YOU: Consider the Beat your DAILY newspaper for up-to-date information about Grant County. It's at your fingertips! One Click to Local News. Thanks for your support for and your readership of Grant County's online news source—

Feel free to notify if you notice any technical problems on the site. Your convenience is my desire for the Beat.  The Beat totally appreciates its readers and subscribers!  

Compliance: Because you are an esteemed member of The Grant County Beat readership, be assured that we at the Beat continue to do everything we can to be in full compliance with GDPR and pertinent US law, so that the information you have chosen to give to us cannot be compromised.